On 31 July, AbbVie announced its H1 2025 results, with total revenue of USD 28.8 billion in the 6-month period, up 7.4% year on year. The immunology, neuroscience, oncology, aesthetics and ophthalmology businesses delivered revenues of USD 13.9 billion (+12.6%), USD 5.0 billion (+20.3%), USD 3.3 billion (+4.2%), USD 2.4 billion (-9.8%) and USD 1.0 billion (-4.8%) respectively.

In immunology, IL-23 antibody Skyrizi (risankizumab) and JAK1 inhibitor Rinvoq (upadacitinib) are both growing rapidly, with their sales now surpassing previous top-seller Humira (adalimumab). In the first half of this year, they generated revenues of USD 7.9 billion (+65.8%) and USD 3.8 billion (+48.5%) respectively, totalling USD 11.6 billion. Given the current high double-digit growth momentum, the immunology duo Skyrizi and Rinvoq could easily surpass AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)AbbVie H1 2025 key product sales (USDm)USD 25 billion in total revenue for the full year.

AbbVie H1 2025 key product sales (USDm)

Former leader Humira has seen declining sales year on year since 2022 due to biosimilar erosion, with sales shrinking to USD 2.3 billion (-54.7%) in the first half of this year.

Decline in Humira sales (USDm); Image from PharmCube's NextBiopharm database
In neuroscience, schizophrenia drug Vraylar (cariprazine) generated sales of USD 1.7 billion (+13.5%) in the first half. Two migraine drugs, Ubrelvy (ubrogepant) and Qulipta (atogepant), performed well, with sales of USD 578 million (+33.3%) and USD 460 million (+63.6%) respectively. Two Parkinson's disease drugs, Duodopa (carbidopa + levodopa) and Vyalev (foslevodopa + foscarbidopa), showed opposite sales trends, with the former having been on the market for over 20 years (USD 193 million, -15.2%) and the latter approved in 2022 and currently ramping up rapidly (USD 161 million).
In oncology, sales of the long marketed BTK inhibitor Imbruvica (ibrutinib) fell 10.7% to USD 1.5 billion in H1. Bcl 2 inhibitor Venclexta (venetoclax) maintained stable growth, with sales reaching USD 1.4 billion (+8.4%).
Among newer products, FRα ADC Elahere (mirvetuximab soravtansine), acquired by AbbVie through its USD 10.1 billion purchase of ImmunoGen, generated revenue of USD 338 million (+75.5%) in the first semester. CD3/CD20 bispecific antibody BsAb Epkinly (epcoritamab), approved in the US in May 2023, delivered revenue of USD 121 million (+92.1%) in H1 2025.
In May this year, AbbVie added another strong player to its oncology portfolio, with telisotuzumab vedotin approved in the US as the first ADC product in the c Met space and AbbVie's first self-developed ADC product.
This year AbbVie has also been highly active in business development transactions. By the end of July, AbbVie had completed 10 deals, a number already close to its annual total in recent years. Two of these deals focused on trispecific assets: in January, AbbVie and Simcere entered into a deal worth over USD 1 billion for the GPRC5D/BCMA/CD3 trispecific SIM0500, and in July it spent USD 1.9 billion to acquire the CD3/BCMA/CD38-targeted ISB 2001.
"AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation", said Robert A. Michael, chairman and CEO. "We're entering the second half of the year with substantial momentum and are once again raising our full-year outlook", he added.